arGentis Pharmaceuticals

arGentis Pharmaceuticals is a privately-held TN pharmaceutical company with a mid-stage orphan drug therapy (ARG201) for advanced diffuse systemic sclerosis (dcSSc). The company is seeking funding to complete the Pivotal clinical trial in order to obtain marketing authorization in the EU. The company has a genotype marker (ROT1) that can predict patient response to treatment through oral tolerance therapy, such as ARG201 for dcSSc.